776.60MMarket Cap-12627P/E (TTM)
5.650High5.260Low1.52MVolume5.580Open5.560Pre Close8.21MTurnover1.19%Turnover RatioLossP/E (Static)143.02MShares12.38052wk High2.16P/B692.04MFloat Cap4.71052wk Low--Dividend TTM127.45MShs Float33.972Historical High--Div YieldTTM7.01%Amplitude1.000Historical Low5.412Avg Price1Lot Size
Aurinia Pharmaceuticals Stock Forum
Larger Image: tradingview.com...
$Aurinia Pharmaceuticals(AUPH.US)$
NEWS
Analysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation’s Spring Clinical Meeting 2024
Aurinia Pharmaceuticals (NASDAQ: AUPH) announced the cost-effectiveness of LUPKYNIS® (voclosporin) for treating lupus nephritis (LN) at the National Kidney Foundation Spring Clinical Meeting 2024. The updated analysis, consistent with a 2021 assessment, utilized the ICER AnalyticsTM LN model and found LUPKYNIS ...
Larger Image: tradingview.com...
$Aurinia Pharmaceuticals(AUPH.US)$
NEWS
The U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical Program
The FDA has approved an updated label for LUPKYNIS, a drug by Aurinia Pharmaceuticals (NASDAQ: AUPH), including long-term data from the AURORA Clinical Program, showing sustained complete renal response through three years. The label now indicates that monthly kidney function assessment is no longer required af...
No comment yet